ABVC BioPharma Balance Sheet Health
Financial Health criteria checks 3/6
ABVC BioPharma has a total shareholder equity of $8.0M and total debt of $1.8M, which brings its debt-to-equity ratio to 22.8%. Its total assets and total liabilities are $14.5M and $6.5M respectively.
Key information
22.8%
Debt to equity ratio
US$1.82m
Debt
| Interest coverage ratio | n/a |
| Cash | US$208.15k |
| Equity | US$7.98m |
| Total liabilities | US$6.48m |
| Total assets | US$14.46m |
Recent financial health updates
Recent updates
ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt
Mar 13
Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute
Oct 05ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug
Sep 23ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?
Aug 18ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M
Aug 17ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial
Jul 13Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute
Jun 30Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?
Apr 04Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Dec 09Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Aug 05Financial Position Analysis
Short Term Liabilities: ABVC's short term assets ($2.1M) do not cover its short term liabilities ($6.3M).
Long Term Liabilities: ABVC's short term assets ($2.1M) exceed its long term liabilities ($167.9K).
Debt to Equity History and Analysis
Debt Level: ABVC's net debt to equity ratio (20.2%) is considered satisfactory.
Reducing Debt: ABVC's debt to equity ratio has reduced from 563.8% to 22.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABVC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ABVC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.2% each year